[10]TRODELVYO(sacituzumab govitecan-hziy)[prescribing information]. Gilead Sciences, Inc., Foster City, CA; 2023.from:https://www.trodelvyhcp.com/ [11]Scott TT, et al.Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (...
Sacituzumab govitecan is a targeted antibody-drug conjugate that may be used to treat adults with the following cancers that have spread (metastasized) or cannot be removed by surgery: triple-negative breast cancer, hormone receptor-positive and human ep
sacituzumab govitecan-hziy responded to treatment, with a median duration of response of 7.2 months (95% CI 4.7-8.6). Also in this case, grade ≥3 treatment-related adverse events were neutropenia and diarrhea (Tagawa et al., 2021). Thus, sacituzumab govitecan-hziy prescribing informat...
Click to learn more about TRODELVY® (sacituzumab govitecan-hziy). See full Prescribing Information, including BOXED WARNING.
Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We conducted a prospective window-of-opportunity ...
Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the ph
Sacituzumab govitecan (SG) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+HER2−) metastatic breast cancer (mBC) in
For patients weighing >170 kg, divide the total dose of sacituzumab govitecan-hziy equally between two 500-mL infusion bags and administer the 2 infusions sequentially. Rate of Administration Infuse initial dose over 3 hours; if infusion-related reactions do not occur, infuse subsequent doses ...
Sacituzumab govitecan-hziy (SG) is a first-in-class antibody and topoisomerase inhibitor conjugate directed at TROP-2, a protein frequently expressed in multiple types of epithelial cancers. SG is approved inthe United St...
Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We